{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:10:16Z","timestamp":1792465816292,"version":"4.5.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"DOI":"10.1007\/s11912-025-01683-1","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T08:54:25Z","timestamp":1746780865000},"page":"748-760","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Role of Transplant for Philadelphia-positive B-cell Acute Lymphoblastic Leukemia in 2025"],"prefix":"10.1007","volume":"27","author":[{"given":"Vaibhav","family":"Agrawal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Koller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Pullarkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Aldoss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,9]]},"reference":[{"key":"1683_CR1","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1182\/asheducation-2015.1.406","volume":"2015","author":"S Chiaretti","year":"2015","unstructured":"Chiaretti S, Foa R. Management of adult Ph-positive acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Program. 2015;2015:406\u201313.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"2","key":"1683_CR2","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1053\/j.seminhematol.2006.01.007","volume":"43","author":"RA Larson","year":"2006","unstructured":"Larson RA. Management of acute lymphoblastic leukemia in older patients. Semin Hematol. 2006;43(2):126\u201333.","journal-title":"Semin Hematol"},{"issue":"1","key":"1683_CR3","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1182\/hematology.2024000532","volume":"2024","author":"MR Luskin","year":"2024","unstructured":"Luskin MR. Ph+ ALL: new approaches for upfront therapy. Hematol Am Soc Hematol Educ Program. 2024;2024(1):78\u201385.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"5","key":"1683_CR4","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1182\/blood.V99.5.1536","volume":"99","author":"B Gleissner","year":"2002","unstructured":"Gleissner B, et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood. 2002;99(5):1536\u201343.","journal-title":"Blood"},{"issue":"8","key":"1683_CR5","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025","volume":"85","author":"RA Larson","year":"1995","unstructured":"Larson RA, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood. 1995;85(8):2025\u201337.","journal-title":"Blood"},{"issue":"7","key":"1683_CR6","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1182\/blood-2002-03-0704","volume":"100","author":"H Dombret","year":"2002","unstructured":"Dombret H, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia\u2013results of the prospective multicenter LALA-94 trial. Blood. 2002;100(7):2357\u201366.","journal-title":"Blood"},{"issue":"12","key":"1683_CR7","doi-asserted-by":"publisher","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","volume":"106","author":"JM Rowe","year":"2005","unstructured":"Rowe JM, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993. Blood. 2005;106(12):3760\u20137.","journal-title":"Blood"},{"issue":"19","key":"1683_CR8","doi-asserted-by":"publisher","first-page":"4489","DOI":"10.1182\/blood-2009-01-199380","volume":"113","author":"AK Fielding","year":"2009","unstructured":"Fielding AK, et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII\/ECOG2993. Blood. 2009;113(19):4489\u201396.","journal-title":"Blood"},{"issue":"22","key":"1683_CR9","doi-asserted-by":"publisher","first-page":"3644","DOI":"10.1200\/JCO.2010.28.1287","volume":"28","author":"R Bassan","year":"2010","unstructured":"Bassan R, et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09\/00. J Clin Oncol. 2010;28(22):3644\u201352.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1683_CR10","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1182\/blood-2006-03-011908","volume":"109","author":"A de Labarthe","year":"2007","unstructured":"de Labarthe A, et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood. 2007;109(4):1408\u201313.","journal-title":"Blood"},{"key":"1683_CR11","doi-asserted-by":"crossref","unstructured":"Fielding AK, Rowe JM, Buck G, et al. UKALLXII\/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood. 2014;123(6):843\u2013850.","DOI":"10.1182\/blood-2013-09-529008"},{"issue":"5","key":"1683_CR12","doi-asserted-by":"publisher","first-page":"653","DOI":"10.3324\/haematol.2014.118588","volume":"100","author":"N Daver","year":"2015","unstructured":"Daver N, et al. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica. 2015;100(5):653\u201361.","journal-title":"Haematologica"},{"issue":"24","key":"1683_CR13","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1182\/blood-2015-02-627935","volume":"125","author":"Y Chalandon","year":"2015","unstructured":"Chalandon Y, et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood. 2015;125(24):3711\u20139.","journal-title":"Blood"},{"issue":"23","key":"1683_CR14","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.1002\/cncr.29646","volume":"121","author":"F Ravandi","year":"2015","unstructured":"Ravandi F, et al. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015;121(23):4158\u201364.","journal-title":"Cancer"},{"issue":"3","key":"1683_CR15","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1182\/bloodadvances.2016001495","volume":"1","author":"F Ravandi","year":"2016","unstructured":"Ravandi F, et al. US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in philadelphia chromosome positive ALL. Blood Adv. 2016;1(3):250\u20139.","journal-title":"Blood Adv"},{"issue":"6","key":"1683_CR16","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1182\/blood-2016-02-700153","volume":"128","author":"P Rousselot","year":"2016","unstructured":"Rousselot P, et al. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood. 2016;128(6):774\u201382.","journal-title":"Blood"},{"issue":"21","key":"1683_CR17","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1182\/blood.V124.21.798.798","volume":"124","author":"OG Ottmann","year":"2014","unstructured":"Ottmann OG, et al. Nilotinib (Tasigna\u00ae) and chemotherapy for first-line treatment in elderly patients with De Novo Philadelphia chromosome\/BCR-ABL1 positive acute lymphoblastic leukemia (ALL): A trial of the European working group for adult ALL (EWALL-PH-02). Blood. 2014;124(21):798.","journal-title":"Blood"},{"issue":"3","key":"1683_CR18","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/ajh.26816","volume":"98","author":"H Kantarjian","year":"2023","unstructured":"Kantarjian H, et al. Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. Am J Hematol. 2023;98(3):493\u2013501.","journal-title":"Am J Hematol"},{"issue":"4","key":"1683_CR19","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.clml.2018.02.010","volume":"18","author":"E Jabbour","year":"2018","unstructured":"Jabbour E, et al. Efficacy of ponatinib versus earlier generation tyrosine kinase inhibitors for front-line treatment of newly diagnosed philadelphia-positive acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2018;18(4):257\u201365.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"23","key":"1683_CR20","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1002\/cncr.30231","volume":"122","author":"K Sasaki","year":"2016","unstructured":"Sasaki K, Jabbour EJ, Ravandi F, et al. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2016;122(23):3650\u20136.","journal-title":"Cancer."},{"issue":"18","key":"1683_CR21","doi-asserted-by":"publisher","first-page":"5395","DOI":"10.1182\/bloodadvances.2022007764","volume":"6","author":"J-M Ribera","year":"2022","unstructured":"Ribera J-M, et al. Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome\u2013positive acute lymphoblastic leukemia. Blood Adv. 2022;6(18):5395\u2013402.","journal-title":"Blood Adv"},{"issue":"7","key":"1683_CR22","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1007\/s12325-023-02497-y","volume":"40","author":"JM Ribera","year":"2023","unstructured":"Ribera JM, et al. Ponatinib vs. imatinib as frontline treatment for philadelphia chromosome-positive acute lymphoblastic leukemia: A matching adjusted indirect comparison. Adv Ther. 2023;40(7):3087\u2013103.","journal-title":"Adv Ther"},{"issue":"21","key":"1683_CR23","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1001\/jama.2024.4783","volume":"331","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, et al. Ponatinib vs imatinib in frontline philadelphia chromosome-positive acute lymphoblastic leukemia: A randomized clinical trial. JAMA. 2024;331(21):1814\u201323.","journal-title":"JAMA"},{"issue":"10","key":"1683_CR24","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1182\/bloodadvances.2019001381","volume":"4","author":"T Badar","year":"2020","unstructured":"Badar T, et al. Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab. Blood Adv. 2020;4(10):2308\u201316.","journal-title":"Blood Adv"},{"issue":"17","key":"1683_CR25","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","volume":"383","author":"R Foa","year":"2020","unstructured":"Foa R, et al. Dasatinib-blinatumomab for Ph-Positive acute lymphoblastic leukemia in adults. N Engl J Med. 2020;383(17):1613\u201323.","journal-title":"N Engl J Med"},{"issue":"8","key":"1683_CR26","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1200\/JCO.23.01075","volume":"42","author":"R Foa","year":"2024","unstructured":"Foa R, et al. Long-term results of the dasatinib-blinatumomab protocol for adult philadelphia-positive ALL. J Clin Oncol. 2024;42(8):881\u20135.","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"1683_CR27","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1182\/blood-2024-207892","volume":"144","author":"S Chiaretti","year":"2024","unstructured":"Chiaretti S, et al. Efficacy and Toxicity of frontline ponatinib plus blinatumomab for adult Ph+ ALL patients of all ages. Intermediate analysis of the gimema ALL2820. Blood. 2024;144(Supplement 1):835\u2013835.","journal-title":"Blood"},{"issue":"7","key":"1683_CR28","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1182\/bloodadvances.2022008216","volume":"7","author":"AS Advani","year":"2023","unstructured":"Advani AS, et al. Dasatinib\/prednisone induction followed by blinatumomab\/dasatinib in Ph+ acute lymphoblastic leukemia. Blood Adv. 2023;7(7):1279\u201385.","journal-title":"Blood Adv"},{"issue":"1","key":"1683_CR29","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","volume":"10","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, et al. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol. 2023;10(1):e24\u201334.","journal-title":"Lancet Haematol"},{"issue":"36","key":"1683_CR30","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.1200\/JCO.24.00272","volume":"42","author":"H Kantarjian","year":"2024","unstructured":"Kantarjian H, et al. Results of the simultaneous combination of ponatinib and blinatumomab in philadelphia chromosome-positive ALL. J Clin Oncol. 2024;42(36):4246\u201351.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1683_CR31","doi-asserted-by":"publisher","first-page":"130","DOI":"10.2991\/chi.k.211119.001","volume":"3","author":"F Fernando","year":"2021","unstructured":"Fernando F, et al. How I use measurable residual disease in the clinical management of adult acute lymphoblastic leukemia. Clin Hematol Int. 2021;3(4):130\u201341.","journal-title":"Clin Hematol Int"},{"issue":"12","key":"1683_CR32","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.3324\/haematol.2022.280638","volume":"107","author":"C Saygin","year":"2022","unstructured":"Saygin C, et al. Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients. Haematologica. 2022;107(12):2783\u201393.","journal-title":"Haematologica"},{"issue":"7","key":"1683_CR33","doi-asserted-by":"publisher","first-page":"e170580","DOI":"10.1001\/jamaoncol.2017.0580","volume":"3","author":"DA Berry","year":"2017","unstructured":"Berry DA, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: A meta-analysis. JAMA Oncol. 2017;3(7):e170580.","journal-title":"JAMA Oncol"},{"issue":"11","key":"1683_CR34","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1038\/leu.2012.164","volume":"26","author":"S Lee","year":"2012","unstructured":"Lee S, et al. Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia. 2012;26(11):2367\u201374.","journal-title":"Leukemia"},{"issue":"4","key":"1683_CR35","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1182\/blood-2016-03-707562","volume":"128","author":"NJ Short","year":"2016","unstructured":"Short NJ, et al. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2016;128(4):504\u20137.","journal-title":"Blood"},{"issue":"20","key":"1683_CR36","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1182\/blood.2022016194","volume":"140","author":"A Ghobadi","year":"2022","unstructured":"Ghobadi A, et al. The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis. Blood. 2022;140(20):2101\u201312.","journal-title":"Blood"},{"issue":"12","key":"1683_CR37","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1002\/ajh.27475","volume":"99","author":"T Badar","year":"2024","unstructured":"Badar T, et al. Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A multi-institutional study. Am J Hematol. 2024;99(12):2388\u201391.","journal-title":"Am J Hematol"},{"issue":"15","key":"1683_CR38","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1002\/cncr.33529","volume":"127","author":"K Sasaki","year":"2021","unstructured":"Sasaki K, et al. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer. 2021;127(15):2648\u201356.","journal-title":"Cancer"},{"issue":"8","key":"1683_CR39","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1002\/ajh.26949","volume":"98","author":"NJ Short","year":"2023","unstructured":"Short NJ, et al. Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1. Am J Hematol. 2023;98(8):1196\u2013203.","journal-title":"Am J Hematol"},{"issue":"26","key":"1683_CR40","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1200\/JCO.24.00108","volume":"42","author":"R Kim","year":"2024","unstructured":"Kim R, et al. Significance of measurable residual disease in adult philadelphia chromosome-positive ALL: A GRAAPH-2014 study. J Clin Oncol. 2024;42(26):3140\u201350.","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"1683_CR41","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1182\/blood-2024-206602","volume":"144","author":"NJ Short","year":"2024","unstructured":"Short NJ, et al. Blinatumomab and ponatinib for adults with newly diagnosed philadelphia chromosome-positive acute lymphoblastic leukemia: updated results and predictors of relapse. Blood. 2024;144(Supplement 1):837\u2013837.","journal-title":"Blood"},{"issue":"2","key":"1683_CR42","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1182\/blood-2014-02-558833","volume":"124","author":"A Stengel","year":"2014","unstructured":"Stengel A, et al. TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis. Blood. 2014;124(2):251\u20138.","journal-title":"Blood"},{"issue":"12","key":"1683_CR43","doi-asserted-by":"publisher","first-page":"e514","DOI":"10.3324\/haematol.2016.161000","volume":"102","author":"N Jain","year":"2017","unstructured":"Jain N, et al. Co-occurrence of CRLF2-rearranged and Ph+ acute lymphoblastic leukemia: a report of four patients. Haematologica. 2017;102(12):e514\u20137.","journal-title":"Haematologica"},{"issue":"12","key":"1683_CR44","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1200\/JCO.2017.74.3617","volume":"36","author":"M Stanulla","year":"2018","unstructured":"Stanulla M, et al. IKZF1(plus) defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric B-cell precursor acute lymphoblastic leukemia. J Clin Oncol. 2018;36(12):1240\u20139.","journal-title":"J Clin Oncol"},{"issue":"31","key":"1683_CR45","doi-asserted-by":"publisher","first-page":"5202","DOI":"10.1200\/JCO.2008.21.6408","volume":"27","author":"G Martinelli","year":"2009","unstructured":"Martinelli G, et al. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J Clin Oncol. 2009;27(31):5202\u20137.","journal-title":"J Clin Oncol"},{"key":"1683_CR46","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood-2019-122017","volume":"134","author":"Y Sasaki","year":"2019","unstructured":"Sasaki Y, et al. Prognostic significance of IKZF1, PAX5, and CDKN2A deletions in patients with philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD\/MA with dasatinib or ponatinib. Blood. 2019;134:2753.","journal-title":"Blood"},{"issue":"11","key":"1683_CR47","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.1038\/s41409-021-01422-7","volume":"56","author":"Y Akahoshi","year":"2021","unstructured":"Akahoshi Y, et al. Newly proposed threshold and validation of white blood cell count at diagnosis for Philadelphia chromosome-positive acute lymphoblastic leukemia: risk assessment of relapse in patients with negative minimal residual disease at transplantation-a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSTCT. Bone Marrow Transplant. 2021;56(11):2842\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"1683_CR48","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","volume":"109","author":"AK Fielding","year":"2007","unstructured":"Fielding AK, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study. Blood. 2007;109(3):944\u201350.","journal-title":"Blood"},{"issue":"12","key":"1683_CR49","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.3324\/haematol.2016.144535","volume":"101","author":"S Chiaretti","year":"2016","unstructured":"Chiaretti S, et al. A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study. Haematologica. 2016;101(12):1544\u201352.","journal-title":"Haematologica"},{"issue":"4","key":"1683_CR50","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1002\/hem3.67","volume":"8","author":"JM Ribera","year":"2024","unstructured":"Ribera JM, et al. Ponalfil trial for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: Long-term results. Hemasphere. 2024;8(4):e67.","journal-title":"Hemasphere"},{"issue":"1","key":"1683_CR51","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41408-024-01055-1","volume":"14","author":"C Wang","year":"2024","unstructured":"Wang C, et al. Refined risk stratification helps guiding transplantation choice in adult BCR::ABL1-positive acute lymphoblastic leukemia. Blood Cancer J. 2024;14(1):71.","journal-title":"Blood Cancer J"},{"issue":"22","key":"1683_CR52","doi-asserted-by":"publisher","first-page":"4439","DOI":"10.1182\/blood-2010-02-266551","volume":"116","author":"M Mohty","year":"2010","unstructured":"Mohty M, et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2010;116(22):4439\u201343.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1683_CR53","doi-asserted-by":"publisher","first-page":"12819","DOI":"10.1182\/blood-2022-164657","volume":"140","author":"T Othman","year":"2022","unstructured":"Othman T, et al. Myeloablative vs reduced-intensity allogeneic hematopoietic cell transplantation in philadelphia-chromosome positive acute lymphoblastic leukemia. Blood. 2022;140(Supplement 1):12819\u201320.","journal-title":"Blood"},{"issue":"3","key":"1683_CR54","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/leu.2013.253","volume":"28","author":"V Bachanova","year":"2014","unstructured":"Bachanova V, et al. Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease. Leukemia. 2014;28(3):658\u201365.","journal-title":"Leukemia"},{"issue":"1","key":"1683_CR55","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1182\/bloodadvances.2021004916","volume":"6","author":"MJ Wieduwilt","year":"2022","unstructured":"Wieduwilt MJ, et al. Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood Adv. 2022;6(1):339\u201357.","journal-title":"Blood Adv"},{"issue":"3","key":"1683_CR56","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/j.bbmt.2019.09.022","volume":"26","author":"Z Warraich","year":"2020","unstructured":"Warraich Z, et al. Relapse prevention with tyrosine kinase inhibitors after allogeneic transplantation for philadelphia chromosome-positive acute lymphoblast leukemia: A systematic review. Biol Blood Marrow Transplant. 2020;26(3):e55\u201364.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"1683_CR57","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3324\/haematol.2014.116954","volume":"100","author":"E Brissot","year":"2015","unstructured":"Brissot E, et al. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. Haematologica. 2015;100(3):392\u20139.","journal-title":"Haematologica"},{"issue":"15","key":"1683_CR58","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1182\/blood.2019004685","volume":"136","author":"N Saini","year":"2020","unstructured":"Saini N, et al. Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL. Blood. 2020;136(15):1786\u20139.","journal-title":"Blood"},{"issue":"1","key":"1683_CR59","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamaoncol.2024.5157","volume":"11","author":"E Jabbour","year":"2025","unstructured":"Jabbour E, et al. Olverembatinib after failure of tyrosine kinase inhibitors, including ponatinib or asciminib: A phase 1b randomized clinical trial. JAMA Oncol. 2025;11(1):28\u201335.","journal-title":"JAMA Oncol"},{"issue":"Supplement 1","key":"1683_CR60","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1182\/blood-2023-186225","volume":"142","author":"M Zhang","year":"2023","unstructured":"Zhang M, et al. Dasatinib and CAR-T cell therapy for newly diagnosed Ph-positive acute lymphoblastic leukemia in adults. Blood. 2023;142(Supplement 1):891\u2013891.","journal-title":"Blood"},{"key":"1683_CR61","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1182\/blood-2024-201784","volume":"144","author":"I Aldoss","year":"2024","unstructured":"Aldoss I, et al. CD19-CAR T cells as definitive consolidation for older adults with B-cell acute lymphoblastic leukemia in first complete remission: A pilot study. Blood. 2024;144:966.","journal-title":"Blood"},{"issue":"17","key":"1683_CR62","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.1182\/bloodadvances.2022009072","volume":"7","author":"LY Chen","year":"2023","unstructured":"Chen LY, et al. Anti-CD19 CAR T-cell consolidation therapy combined with CD19+ feeding T cells and TKI for Ph+ acute lymphoblastic leukemia. Blood Adv. 2023;7(17):4913\u201325.","journal-title":"Blood Adv"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01683-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-025-01683-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01683-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T07:04:08Z","timestamp":1751612648000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-025-01683-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":62,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["1683"],"URL":"https:\/\/doi.org\/10.1007\/s11912-025-01683-1","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,9]]},"assertion":[{"value":"25 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors do not have any financial or non-financial interests that directly or indirectly relate to this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}